Caliway Biopharmaceuticals C stock at TWD 77.20 on October 12, 2026, 2.8% above low
Published on 10/12/2026 at 14:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Caliway Biopharmaceuticals C was last quoted at TWD 77.20 on October 12, 2026.
- The price stood 2.80 percent above the TWD 75.10 52-week low.
- Second-quarter 2026 revenue was TWD 3.57 million and net loss was TWD 222.52 million.
- The next earnings date is listed as November 11, 2026.
Caliway Biopharmaceuticals C (TW0006919004) was last quoted at TWD 77.20 on the Taiwan Stock Exchange on October 12, 2026 at 1:30 p.m. TST, placing the price 2.80 percent above its 52-week low of TWD 75.10. The stock's market value was TWD 120.1 billion, while its price-to-earnings ratio stood at minus 478.61 on the same date.
Price remains near yearly low
The current quote sits TWD 2.10 above the 52-week low and TWD 110.80 below the TWD 188.00 high. That spread puts the shares near the lower end of their annual range, a useful market-position measure for a development-stage biotechnology company.
The company also reported a subdued operating base for the second quarter of 2026. According to Investing.com, revenue was TWD 3.57 million and net loss was TWD 222.52 million in the quarter, with diluted earnings per share of minus TWD 0.14. The figures give the market valuation a clinical-development rather than earnings-growth context.
Valuation and cash position
At June 30, 2026, Caliway held TWD 3.05 billion in cash and cash equivalents plus TWD 1.00 billion in short-term investments. Total assets were TWD 9.43 billion, while operating cash flow was negative TWD 129.10 million in the second quarter.
The balance sheet therefore remains an important part of the price report. The company had TWD 5.06 billion in long-term investments at June 30, 2026, against total debt of TWD 107.95 million, according to the reported quarterly financial data.
Comparison with peers
Caliway Biopharmaceuticals C: P/E minus 478.61, market capitalization TWD 120.1 billion
Lin BioScience (TWO, TWD): minus 2.00 percent, P/E minus 12.31, market capitalization TWD 142.2 billion
Medigen Vaccine Biologics (TWO, TWD): minus 6.13 percent, P/E minus 113.27, market capitalization TWD 19.1 billion
Next reporting date
Investing.com lists November 11, 2026 as the next reporting date. The calendar date gives the market a defined point for comparing the company's clinical progress with its financial runway.
Caliway Biopharmaceuticals C market data
- Company: Caliway Biopharmaceuticals Co., Ltd.
- ISIN: TW0006919004
- Ticker: 6919
- Primary exchange: Taiwan Stock Exchange
- Price Taiwan Stock Exchange: TWD 77.20 as of October 12, 2026 at 1:30 p.m. TST
- Market capitalization: TWD 120.1 billion as of October 12, 2026
- 52-week range: TWD 75.10-TWD 188.00 as of October 12, 2026
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: TAIEX
- Next earnings date: November 11, 2026
Market context: Market report TAIEX.
More news and analyses on Caliway Biopharmaceuticals C stock
